Heineken에 대한 매도 수량은 투자자에게 Heineken의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Heineken (OTC:HEINY) 주식, 공매도 수량 보고

Heineken

Heineken sold 243 million hectoliters of beer in 2023, and is the world's second-largest brewer behind Anheuser-Busch InBev. It has the leading position in many European markets, including the Netherlands, Austria, Greece, and Italy. Its flagship brand, Heineken, is the world's leading international premium lager by volume and has spawned several brand extensions including Heineken 0.0 and Heineken Silver. Heineken is the world's biggest cider producer, and its portfolio also includes brands in the nonalcoholic, Belgian, and craft beer categories.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

ADDYY

HEINY

LULU

NDAQ

RBLX

VWAGY

밈 암호화폐인 도지코인(CRYPTO: DOGE)은 지난 한 주 동안 80% 이상 상승하며 52주 신고가를 경신하는 등 가격과 가치가 급등하고 있다.
최근의 가치 상승으로 도지코인은 일부 유명 글로벌 기업의 가치를 넘어섰다.

급등한 도지코인: 포드, 아디다스, 룰루레몬, 로블록스 등 15개 기업보다 시가총액 높아

Global

Markets

General

ORLY

국제 항만 노동자 협회(ILA)는 임금 인상과 자동화 및 인공 지능(AI)에 대한 보호 조치를 두고 진행 중인 협상 중에 이번 주 초 파업을 시작했다. 이번 파업이 장기화될 경우 공급 제약이 발생해 가격 상승을 초래할 수 있다고 경제학자들은 경고하고 있다.

맥주 부족 예정? 美 항구 파업으로 가장 영향받을 3가지 제품

Heineken NV

News

NGNE

Neurogene Says Participant In Ongoing Phase 1/2 Clinical Trial For Rett Syndrome Who Was Dosed On November 5 With 3E15 vg Of NGN-401 And Was Previously In Critical Condition, Has Died

Earnings

CAMP

CAMP4 Therapeutics Q3 EPS $(24.19), Ended Quarter With $2.5M In Cash And Cash Equivalents

<ul>
<li>Cash and cash equivalents at €13.9 million, as of September 30, 2024.</li>
<li>Revenues of €1.3 million for the first nine months of 2024.</li>
<li>On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.</li>
<li>Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 20253.</li>
</ul>
 &nbsp;

Inventiva Reports Revenues Of €1.3 Million For The First 9-Months Of 2024

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) reported quarterly earnings of $0.37 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.146 billion which beat the analyst consensus estimate of $1.100 billion by 4.19 percent. This is a 12.35 percent increase over sales of $1.020 billion the same period last year.

Earnings Beats

CPRT

Copart Q1 2025 GAAP EPS $0.37, Inline, Sales $1.146B Beat $1.100B Estimate

Regulators are looking to block Google <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">from investing $2 billion</a> in Antrophic, a Jeff Bezos-backed rival to artificial intelligence (AI) innovator OpenAI. 
What Happened: The U.S. Department of Justice (DOJ) recommended in <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">a court filing Wednesday</a> that Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google divest its Chrome browser to dismantle its monopoly on online search. 
It doesn&#8217;t end there. Google should be barred from doing any deals with companies that control where consumers search for information, regulators say. That includes AI products. This puts Google's Anthropic investment at risk, according to <a href="https://www.bloomberg.com/news/articles/2024-11-21/us-justice-department-seeks-to-unwind-google-s-anthropic-deal">Bloomberg</a>, citing unnamed sources.
Also Read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a>
Google boasts over 91% global market share when it comes to online search, per&nbsp;<a href="https://gs.statcounter.com/search-engine-market-share" target="_blank" rel="noreferrer noopener">GlobalStats</a>.&nbsp;
Why It Matters: Google needs Anthropic, or startups like it. Without it, Google is at a disadvantage, considering every major tech company is essentially in an AI arms race. 
Since OpenAI&#8217;s ChatGPT launch in late 2022, tech giants have heavily invested in AI startups.
But Google&#8217;s Anthropic deal is raising concerns overseas as well.
Last month, U.K. antitrust officials announced an investigation into whether Google&#8217;s pursuit of Anthropic <a href="https://www.gov.uk/cma-cases/alphabet-inc-google-llc-slash-anthropic-merger-inquiry" target="_blank" rel="noreferrer noopener">could harm competition</a>. 
Meanwhile, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) managed to avoid scrutiny. <a href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog" target="_blank" rel="noreferrer noopener">The UK&#8217;s competition regulator</a> recently approved the partnership between Amazon and Anthropic, despite the Seattle-based company&#8217;s significant $4 billion investment in the company.
Britain&#8217;s Competition and Markets Authority (CMA) confirmed the partnership does not fall under its jurisdiction.
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) also appeased regulators when it <a href="https://www.benzinga.com/markets/equities/24/07/39703459/microsoft-relinquishes-observer-role-on-openais-board-says-it-is-confident-in-companys-direction" target="_blank" rel="noreferrer noopener">relinquished its board observer</a> role at OpenAI. The Redmond, Washington-based company invested over $10 billion in the AI startup.
What&#8217;s Next: A decision on whether the UK will require further investigation is expected by Dec. 19.
In the U.S., Google plans to appeal Judge Amit Mehta&#8216;s <a href="https://www.benzinga.com/government/24/08/40169996/alphabet-loses-antitrust-suit-over-google-search-dominance-report">antitrust ruling in August</a>. 
Mehta&#8217;s decision could ultimately lead to Google divesting segments of its business, <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">including Chrome</a>.
Price Action: Alphabet was down 4.5% to $169.24 on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121525/microstrategy-surges-674-in-2024-5-etfs-that-benefit-from-mstrs-bitcoin-driven-growth">MicroStrategy Surges 674% In 2024: 5 ETFs That Benefit From MSTR&#8217;s Bitcoin-Driven Growth</a></li>
</ul>
Image: Shutterstock

Politics

Tech

AMZN

GOOG

GOOGL

MSFT

Google, Anthropic Deal In Jeopardy As US Justice Department Looks To Snap Online Search Monopoly

Contracts

SNOA

Sonoma Pharmaceuticals Terminates Agreement With EMC Pharma After It Did Not Meet Minimum Purchase Requirements

Buybacks

EGAN

eGain Board Approves Extension To Stock Repurchase Program From Nov. 14 Until The Earlier Of The Date The Aggregate Amount Of Shares That Can Be Repurchased Under The Stock Repurchase Program Have Been Repurchased And November 14, 2025

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.
CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1
Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.

Biotech

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

BGC Group's Howard Lutnick To Divest Interests And Step Down From Roles At Cantor, BGC, And Newmark Pending Senate Confirmation; Corporate Structure To Remain Unchanged With John Abularrage, Jean-Pierre Aubin, And Sean Windeatt Recommended As Co-CEOs

Myers Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>), a leading manufacturer of a wide range of polymer and metal products and distributor for the tire, wheel and under-vehicle service industry (the "Company" or "Myers"), today announced that its Board of Directors (the "Board") has appointed Aaron M. Schapper as the Company's new President and Chief Executive Officer, effective January 1, 2025. Mr. Schapper will succeed Dave Basque, who has been serving as Myers' Interim President and CEO since September 9, 2024, and who will return to his role as Vice President, Special Projects. Mr. Schapper will also join the Board in January.

Management

Myers Industries Appoints Aaron Schapper As President, Chief Executive Officer And Director Effective January 1, 2025; Dave Basque, Who Has Been Serving As Myers' Interim President And CEO Since September 9, 2024, Will Return To His Role As Vice President, Special Projects

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)
IND enabling studies underway, with Phase I initiation expected in Q425

PTGX

Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease

Alta Global Group Files Request For Withdrawal Of Its Registration Statement On Form F-1 With SEC, Initially Filed On September 5, 2024

<a href="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf</a> &nbsp;

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or Within Seven Days Of FDA's New Decision

The earnings results for Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) for Q2 were made public on Thursday, November 21, 2024 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Logility Supply Chain beat estimated earnings by 22.0%, reporting an EPS of $0.11 versus an estimate of $0.09.
Revenue was down $404 thousand from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.04, leading to a 8.0% increase share price change the next day.
Here's a look at Logility Supply Chain's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.08</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.12</td>
<td>0.12</td>
<td>0.19</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>25.26M</td>
<td>25.12M</td>
<td>24.81M</td>
<td>28.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>26.19M</td>
<td>25.39M</td>
<td>25.54M</td>
<td>25.69M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Logility Supply Chain <a href="https://www.benzinga.com/quote/LGTY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGTY

Logility Supply Chain: Q2 Earnings Insights

Offerings

MODD

Modular Medical Announces Proposed Public Offering; Terms Not Disclosed

Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) announced its Q2 earnings on Thursday, November 21, 2024 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Elastic beat estimated earnings by 55.00000000000001%, reporting an EPS of $0.59 versus an estimate of $0.38.
Revenue was up $54.75 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.1, leading to a 26.0% drop share price change the next day.
Here's a look at Elastic's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.25</td>
<td>0.20</td>
<td>0.31</td>
<td>0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.21</td>
<td>0.36</td>
<td>0.37</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>344.70M</td>
<td>329.48M</td>
<td>320.29M</td>
<td>304.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>347.42M</td>
<td>335.00M</td>
<td>327.96M</td>
<td>310.61M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Elastic <a href="https://www.benzinga.com/quote/ESTC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESTC

Earnings Summary: Elastic Q2

Health Care

Sonoma Pharmaceuticals Relaunches Its Prescription Dermatology And Eye Care Product Lines In The US

Warner Music Group Files For Mixed Shelf; Size Not Disclosed

Farrell will continue to report directly to Nazar Khan, Chief Technology Officer of TeraWulf.

WULF

TeraWulf Promotes Sean Farrell To COO, Effective Immediately

VRPX

Virpax Pharmaceuticals Announces An Agreement With The U.S. HHS Department An Extension Of Its Cooperative Research And Development Agreement

Analyst Zheng Feng Chee of DBS maintained a Buy rating on Heineken NV (0O26 – Research Report), with a price target of €104.00. Zheng Feng Chee has...

Heineken NV: Strategic Brand Extensions and Sustainable Growth Drive Buy Rating

Barclays lowered the firm's price target on Heineken (HEINY) to EUR 90 from EUR 92 and keeps an Overweight rating on the shares. Published first on...

Heineken price target lowered to EUR 90 from EUR 92 at Barclays

In a report released on October 23, James Edwardes Jones from RBC Capital maintained a Sell rating on Heineken NV (0O26 – Research Report), with a ...

RBC Capital Sticks to Its Sell Rating for Heineken NV (0O26)

Kepler Capital analyst Richard Withagen maintained a Buy rating on Heineken NV (0O26 – Research Report) on October 23 and set a price target of €98...

Kepler Capital  Keeps Their Buy Rating on Heineken NV (0O26)

Artisan International Fund Q3 2024 Commentary

Morgan Stanley lowered the firm's price target on Heineken (HEINY) to EUR 81 from EUR 83 and keeps an Equal Weight rating on the shares. Published ...

Heineken price target lowered to EUR 81 from EUR 83 at Morgan Stanley

It's National American Beer Day: These are the top-selling beers in the U.S.

Goldman Sachs analysts removed Heineken (HEINY) from the firm's European Conviction List as part of its monthly update. Published first on TheFly –...

Heineken removed from European Conviction List at Goldman Sachs

Warning: HEINY is at high risk of performing badly

BlackRock International Fund Q3 2024 Commentary

ACCYY

ACRFF

ADDDF

AIQUF

AIQUY

ARGNF

ARGX

ASML

ASMLF

AZNCF

BDRFF

BDRFY

DTEGF

DTEGY

EADSF

EADSY

ENGIY

ENGQF

HINKF

INTC

JPPTY

JPSTF

LSRCF

LSRCY

MLSPF

NGGTF

NONOF

NPXYY

OTSKF

OTSKY

PDRDF

PRNDY

RCRRF

RCRUY

RSNHF

SMFG

SMFNF

SNEJF

SONY

SSNLF

TCEHY

TCTZF

TMNSF

TMSNY

TMUS

TWODF

TWODY

TYNPF

UCBJF

UCBJY

Sports

Press Releases

Heineken® Says "Cheers To The Real Hardcore Fans," – But They Aren't Who You Think

Heineken® Celebrates Historic Irish Pubs With Virtual Museums Launch

Heineken® shows the depth it will go to deliver the perfect pint with giant spirit level measuring bars across the world

Dialing Up Nights Out: Heineken® & Bodega Launch the No-Frills 'Boring Phone'

Heineken Silver is on a mission to end bitterness, starting with one of the biggest love-hate relationships in Marvel Studios' "Deadpool & Wolverine"

Heineken® Celebrates Thousands of 'Real Hardcore Fans' by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever

On International Beer Day, Heineken® says you can forget about the beer

Heineken Hides Message in Barry Can't Swim Show at Amsterdam Dance Event Calling for People to Put Away Their Phones

HKHHY

Comments

Heineken

매도 수량

Heineken (OTC:HEINY) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌